Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

Dalva-Aydemir, SEVİM; Bajpai, Richa; Martinez, Maylyn; Adekola, Kehinde; Kandela, Irawati; Wei, Changyong; Singhal, Seema; Koblinski, Jennifer; Raje, Noopur; Rosen, Steven; Shanmugam, Mala

doi:10.1158/1078-0432.ccr-14-1088

Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

Dalva-Aydemir S., Bajpai R., Martinez M., Adekola K. U. A., Kandela I., Wei C., ...Daha Fazla

CLINICAL CANCER RESEARCH, cilt.21, sa.5, ss.1161-1171, 2015 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 21 Sayı: 5
Basım Tarihi: 2015
Doi Numarası: 10.1158/1078-0432.ccr-14-1088
Dergi Adı: CLINICAL CANCER RESEARCH
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1161-1171
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Ankara Üniversitesi Adresli: Hayır

Özet

Purpose: We have previously demonstrated that ritonavir targeting of glycolysis is growth inhibitory and cytotoxic in a subset of multiple myeloma cells. In this study, our objective was to investigate themetabolic basis of resistance to ritonavir and to determine the utility of cotreatment with the mitochondrial complex I inhibitor metformin to target compensatory metabolism.